Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,774 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. Tada T, et al. Among authors: kim sr, kim sk. Infect Dis Ther. 2021 Mar;10(1):269-280. doi: 10.1007/s40121-020-00364-9. Epub 2020 Nov 3. Infect Dis Ther. 2021. PMID: 33141401 Free PMC article.
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.
Kaneko S, Sata M, Ide T, Yamashita T, Hige S, Tomita E, Mochida S, Yamashita Y, Inui Y, Kim SR, Komada N, Mikami T, Satoh S, Morita S, Takaguchi K, Hirashima N, Nishio Y, Watanabe D, Kioka K, Fujiwara K. Kaneko S, et al. Among authors: kim sr. Hepatol Res. 2010 Nov;40(11):1072-81. doi: 10.1111/j.1872-034X.2010.00708.x. Epub 2010 Sep 28. Hepatol Res. 2010. PMID: 20880058
Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment.
Takashima T, Enomoto H, Ninomiya T, Kim SR, Okushin H, Sugano M, Imoto S, Yano Y, Ooka T, Seo Y, Kasugai H, Muramatsu A, Jomura H, Shimomura S, Shindo M, Nakamura H, Aizawa N, Iwata Y, Saito M, Imanishi H, Iijma H, Nishiguchi S. Takashima T, et al. Among authors: kim sr. Hepatol Res. 2014 Jun;44(6):597-607. doi: 10.1111/hepr.12153. Epub 2013 May 31. Hepatol Res. 2014. PMID: 23639109
Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy.
Sugimoto K, Kim SR, El-Shamy A, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, Kudo M. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Dig Dis. 2013;31(5-6):434-9. doi: 10.1159/000355241. Epub 2013 Nov 21. Dig Dis. 2013. PMID: 24281017 Free article. Clinical Trial.
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, Kudo M, Hayashi Y. Sugimoto K, et al. Among authors: kim sr, kim sk, kim ki. Oncology. 2015;89 Suppl 2:42-6. doi: 10.1159/000440630. Epub 2015 Nov 19. Oncology. 2015. PMID: 26584035
1,774 results